Lynx Dx

22/07/2025

What does the research really say about diet and prostate cancer risk?

While the evidence is still evolving, studies continue to explore how dietary factors like lycopene, phytochemicals, and fatty acids may influence prostate cancer risk. This blog outlines both well-established insights (e.g., the benefits of plant-based antioxidants) and areas of active investigation helping providers stay informed about nutrition’s potential role in prevention.

Read more:
https://bit.ly/44Riw46

Research has added clarity to the relationship between diet and prostate cancer, including the role of antioxidants, phytochemicals, fatty acids, and processed meats

15/07/2025

ICYMI: Dr. Jacob Meyers and Dr. Jeff Tosoian recently joined the Dr. Geo Podcast to discuss MyProstateScore 2.0 (MPS2), a clinically validated, noninvasive biomarker test for assessing the risk of clinically significant prostate cancer.

Highlights include:

1. How MPS2 complements PSA-based assessments
2. Advantages of its 18-gene urinary biomarker panel
3. Identifying patients who may safely defer biopsy
4. Real-world flexibility and utility of noninvasive urine collection
5. Clinical validation and performance data

Click the links below to listen to both full episodes:
1. Dr. Jacob Meyers – https://bit.ly/4lEFVNl
2. Dr. Jeff Tosoian – https://bit.ly/4ePZRKB

14/07/2025

We’re on the road this July!

Come meet the Lynx Dx team and explore how MyProstateScore 2.0 (MPS2) is advancing prostate cancer risk assessment. No DRE required.

Let’s talk about how MPS2 supports decisions about whether to proceed with biopsy, adds clarity alongside PSA, and fits seamlessly into clinical workflows.

https://bit.ly/44HZL30

08/07/2025

We’re pleased to welcome Ryan Mitton to Lynx Dx as Director of Marketing and Customer Experience.

Ryan brings over 20 years of experience in product marketing, go-to-market strategy, and customer experience. He spent nearly two decades at Ford Motor Company, where he developed deep strategic expertise and a strong track record of success.

At Lynx Dx, Ryan will lead our strategic marketing initiatives and drive an integrated, customer-first experience across all touch points.

Please join us in welcoming Ryan to the team!

04/07/2025

Happy 4th of July from all of us at Lynx Dx!

Wishing you a safe and healthy Independence Day.

01/07/2025

PSA doesn’t always tell the full story.

MyProstateScore 2.0 is an advanced, noninvasive risk assessment test that helps providers evaluate the need for biopsy with greater clarity.

It offers deeper insight for patients with elevated or borderline PSA levels, supporting informed decision-making.

How are you approaching PSA gray zones?

Learn more: https://bit.ly/3HwHwC2

30/06/2025

PSA, the traditional method to screen for prostate cancer, isn’t enough.

In this episode of the podcast with Dr. Geo, Dr. Jacob Meyers, Director of Research & Development, breaks down how MyProstateScore 2.0 offers patients a simple urine test that helps better predict the likelihood of clinically significant prostate cancer.

Listen: https://bit.ly/4lBl5hE

24/06/2025

Here at Lynx Dx, we’re proud to spotlight the people powering our mission during Men’s Health Month 2025.

This year’s theme, “closing the empathy gap,” reminds us that real change starts with action.

One example of that action is MyProstateScore 2.0 (MPS2), a noninvasive test designed to support more informed, confident biopsy decisions.

And behind every test are passionate team members like Nick and Dylan. They are deeply committed to transforming the future of men’s health.

1. Nick Meyer, Lab Manager
Nick oversees our lab operations, ensuring every MPS2 test is processed with accuracy and care.

2. Dylan Vanoverbeke, Accessioning Manager
Dylan is responsible for meticulously entering patient data, laying the foundation for precise, reliable results that impact men’s health directly.

Swipe to hear what drives them.

Discover MPS2: a better path to prostate screening.
ttps://www.lynxdx.com/my-prostate-score/providers/

17/06/2025

Dr. Jeff Tosoian shares why PSA testing isn’t enough on its own and how MyProstateScore 2.0 (MPS2) gives doctors the clarity they need when it matters most.

Watch the clip from AUA here: https://bit.ly/3FALEE6

The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for Grade Group≥2 (GG≥2) prostate cancer (PCa) using post-DRE urine. To facilitate at-ho...

10/06/2025

The majority of prostate biopsies come back negative for clinically significant cancer. So, how can we help these men safely avoid the pain, discomfort, and potential complications they can cause?

On the Dr. Geo Podcast, Dr. Jeff Tosoian discusses how advanced biomarker tests like MyProstateScore 2.0 (MPS2) are helping urologists more confidently predict the presence of clinically significant prostate cancer and determine who can safely avoid a biopsy.

Listen here: https://apple.co/3ZVHYni

03/06/2025

Lynx Dx is proud to support the June A2 BioSocial as a Silver Sponsor.

We’ll be at HOMES Campus Beer Garden today in Ann Arbor. Stop by our table to meet our Director of R&D, Jacob Meyers, and the rest of the Lynx Dx crew and learn more about the next generation in prostate cancer risk assessment.



https://bit.ly/3T7uYqQ

29/05/2025

Providers now have a clearer path forward.

MPS2 is a simple urine test that predicts the presence of clinically significant prostate cancer; no DRE required.

1. At-home or in-office collection
2. Results in 5–7 business days
3. Online quick ordering or via paper form

Help patients avoid unnecessary procedures and gain peace of mind. https://bit.ly/430RWop